Completed × Intraocular Lymphoma × Rituximab × Clear all
NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

University of Chicago

Phase 1/2 Completed
55 enrolled 17 charts
NCT01326702 2019-12-16

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
43 enrolled 18 charts
NCT00867529 2018-01-02

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed
63 enrolled 12 charts
NCT00072514 2017-06-29

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
55 enrolled 6 charts
NCT00416923 2015-02-16

Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

University of California, San Francisco

Phase 1 Completed
10 enrolled
NCT00054639 2014-05-28

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
48 enrolled 5 charts